Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Jennifer Diamond

Concepts (287)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
201
6.450
 Why?
Breast Neoplasms
24
2025
2239
4.310
 Why?
Immunoconjugates
7
2023
114
2.510
 Why?
Antineoplastic Agents
23
2023
2129
2.510
 Why?
Antineoplastic Combined Chemotherapy Protocols
20
2025
1683
2.470
 Why?
Pyrimidines
9
2021
470
2.330
 Why?
Receptor, ErbB-2
12
2025
342
2.090
 Why?
Protein Kinase Inhibitors
11
2025
916
1.830
 Why?
Piperazines
4
2020
350
1.650
 Why?
Paclitaxel
6
2022
227
1.570
 Why?
Camptothecin
9
2023
114
1.560
 Why?
Neoplasms
14
2022
2644
1.520
 Why?
Pyrazoles
6
2021
423
1.360
 Why?
Ovarian Neoplasms
5
2025
563
1.300
 Why?
Quinoxalines
2
2020
66
1.290
 Why?
Antibodies, Monoclonal, Humanized
10
2024
804
1.240
 Why?
Azepines
3
2020
90
1.220
 Why?
Histone Deacetylase Inhibitors
4
2024
210
1.180
 Why?
Cyclin-Dependent Kinase 4
2
2018
47
1.080
 Why?
Cyclin-Dependent Kinase 6
2
2018
42
1.070
 Why?
Neutropenia
4
2022
146
0.870
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1396
0.760
 Why?
Xenograft Model Antitumor Assays
11
2021
864
0.730
 Why?
Breast Neoplasms, Male
2
2018
28
0.730
 Why?
beta Catenin
2
2020
251
0.720
 Why?
Female
51
2025
72840
0.680
 Why?
Chemotherapy, Adjuvant
4
2023
390
0.680
 Why?
Maximum Tolerated Dose
9
2022
198
0.670
 Why?
Benzoxazoles
1
2020
19
0.670
 Why?
Cancer Care Facilities
1
2020
38
0.670
 Why?
Receptors, Estrogen
3
2021
436
0.670
 Why?
Carcinoma, Lobular
2
2018
49
0.660
 Why?
eIF-2 Kinase
1
2019
31
0.640
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
209
0.630
 Why?
Tumor Microenvironment
4
2024
671
0.610
 Why?
Anthracyclines
3
2023
48
0.600
 Why?
Humans
64
2025
136783
0.590
 Why?
Taxoids
3
2023
104
0.590
 Why?
Aged
24
2025
23729
0.560
 Why?
Carcinoma, Ductal, Breast
1
2018
83
0.560
 Why?
Aurora Kinase A
4
2020
56
0.560
 Why?
Drug Resistance, Neoplasm
4
2020
800
0.550
 Why?
Wnt Signaling Pathway
1
2019
192
0.550
 Why?
Trastuzumab
4
2023
101
0.550
 Why?
Pyridines
3
2025
505
0.540
 Why?
Pyrazines
2
2018
91
0.520
 Why?
Myocardial Infarction
1
2023
1045
0.500
 Why?
Colonic Neoplasms
1
2018
256
0.500
 Why?
Tumor Suppressor Protein p53
4
2024
530
0.480
 Why?
Neoadjuvant Therapy
1
2018
403
0.480
 Why?
Angiopoietin-1
1
2015
11
0.480
 Why?
Neoplasm Recurrence, Local
5
2025
1055
0.480
 Why?
Angiopoietin-2
1
2015
16
0.480
 Why?
Nuclear Proteins
2
2023
710
0.470
 Why?
Medicare
4
2023
747
0.440
 Why?
Uterine Cervical Neoplasms
1
2017
254
0.430
 Why?
Middle Aged
25
2025
33200
0.420
 Why?
Cell Line, Tumor
9
2022
3399
0.420
 Why?
Colorectal Neoplasms
5
2022
792
0.410
 Why?
Radiosurgery
3
2025
345
0.400
 Why?
Dose-Response Relationship, Drug
6
2022
2045
0.390
 Why?
Adult
26
2025
37616
0.390
 Why?
Antibodies, Monoclonal
4
2024
1428
0.390
 Why?
Tumor Suppressor Proteins
1
2015
327
0.390
 Why?
Treatment Outcome
13
2025
10764
0.390
 Why?
Proto-Oncogene Proteins c-met
1
2013
75
0.390
 Why?
Cell Proliferation
8
2020
2473
0.390
 Why?
Antineoplastic Agents, Immunological
3
2019
189
0.380
 Why?
Recombinant Fusion Proteins
1
2015
663
0.380
 Why?
Point Mutation
1
2013
234
0.380
 Why?
Triazoles
1
2013
147
0.370
 Why?
Angiogenesis Inhibitors
3
2018
226
0.360
 Why?
Aged, 80 and over
10
2025
7569
0.350
 Why?
Mice, Nude
6
2020
692
0.350
 Why?
Quinolines
3
2025
177
0.350
 Why?
Clinical Trials, Phase I as Topic
2
2020
51
0.340
 Why?
Carcinoma, Renal Cell
1
2013
214
0.340
 Why?
Mitochondria
1
2017
946
0.340
 Why?
Heart Failure
1
2023
2228
0.330
 Why?
Histones
3
2023
635
0.330
 Why?
Genes, BRCA2
1
2009
29
0.330
 Why?
Neoplasm Metastasis
4
2020
654
0.320
 Why?
Genes, BRCA1
1
2009
38
0.320
 Why?
Biomarkers, Tumor
2
2014
1274
0.310
 Why?
Molecular Targeted Therapy
3
2019
413
0.310
 Why?
BRCA2 Protein
1
2009
63
0.310
 Why?
Pregnancy Complications, Neoplastic
1
2009
51
0.310
 Why?
Thrombophilia
1
2009
84
0.300
 Why?
Neoplasm Staging
5
2021
1373
0.300
 Why?
Lung Neoplasms
2
2024
2491
0.300
 Why?
Apoptosis
7
2024
2548
0.300
 Why?
Kidney Neoplasms
1
2013
400
0.290
 Why?
Aromatase Inhibitors
2
2018
53
0.290
 Why?
Receptors, Progesterone
2
2021
349
0.280
 Why?
DNA-Binding Proteins
1
2015
1500
0.270
 Why?
Models, Biological
1
2014
1769
0.260
 Why?
Mice
9
2021
17731
0.250
 Why?
Doxorubicin
3
2024
365
0.240
 Why?
Cyclophosphamide
2
2018
248
0.220
 Why?
Disease Models, Animal
3
2021
4279
0.200
 Why?
United States
5
2023
14660
0.200
 Why?
Brain Neoplasms
3
2025
1241
0.200
 Why?
Liver Neoplasms
1
2009
784
0.200
 Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.190
 Why?
Animals
11
2021
36768
0.190
 Why?
Biopsy
2
2018
1126
0.190
 Why?
Histone Deacetylase 1
1
2022
25
0.190
 Why?
Aurora Kinases
2
2012
27
0.190
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
44
0.190
 Why?
Administration, Oral
3
2022
808
0.190
 Why?
Topoisomerase I Inhibitors
2
2022
16
0.190
 Why?
Disease Progression
4
2019
2750
0.180
 Why?
Fluorouracil
1
2022
210
0.180
 Why?
Acetylation
1
2022
248
0.180
 Why?
Arrhythmias, Cardiac
1
2023
331
0.180
 Why?
Biliary Tract Neoplasms
1
2021
30
0.170
 Why?
Androstadienes
1
2021
107
0.170
 Why?
Diarrhea
2
2019
183
0.170
 Why?
Carboplatin
1
2021
143
0.170
 Why?
Heterografts
1
2021
138
0.170
 Why?
Hospitals, University
1
2021
180
0.170
 Why?
Drug Administration Schedule
3
2017
783
0.170
 Why?
Necrosis
2
2019
244
0.170
 Why?
Histone Deacetylases
1
2022
214
0.170
 Why?
Fatigue
2
2022
327
0.170
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.160
 Why?
Immunotherapy
2
2023
640
0.160
 Why?
Clinical Trials as Topic
3
2016
1043
0.160
 Why?
Immune System
1
2021
177
0.160
 Why?
Benzodiazepines
1
2021
152
0.160
 Why?
Male
13
2021
67361
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
40
0.160
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
125
0.160
 Why?
Kaplan-Meier Estimate
1
2021
891
0.160
 Why?
Tumor Cells, Cultured
1
2020
953
0.150
 Why?
Albumins
1
2019
113
0.150
 Why?
Aquaporin 4
1
2019
94
0.150
 Why?
Maintenance Chemotherapy
1
2018
35
0.150
 Why?
Nausea
1
2018
111
0.140
 Why?
Aminopyridines
1
2018
99
0.140
 Why?
Vascular Endothelial Growth Factor A
2
2018
544
0.140
 Why?
Antibodies, Bispecific
1
2018
54
0.140
 Why?
Mice, Inbred BALB C
1
2020
1267
0.140
 Why?
Drug Therapy, Combination
1
2020
1059
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
217
0.140
 Why?
Breast
1
2018
150
0.140
 Why?
Purines
1
2018
176
0.140
 Why?
Benzimidazoles
1
2018
168
0.140
 Why?
Mastectomy
1
2018
136
0.140
 Why?
Topotecan
1
2017
13
0.140
 Why?
Isoflavones
1
2017
26
0.140
 Why?
Imidazoles
1
2018
239
0.130
 Why?
Calcium-Binding Proteins
1
2018
218
0.130
 Why?
Survival Analysis
1
2020
1319
0.130
 Why?
Carbolines
1
2017
32
0.130
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
20
0.130
 Why?
Inhibitory Concentration 50
2
2016
90
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2019
250
0.130
 Why?
Retrospective Studies
4
2025
15564
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
92
0.130
 Why?
Cell Survival
1
2019
1117
0.120
 Why?
Insulin-Like Growth Factor I
1
2018
316
0.120
 Why?
Hypertension
2
2018
1284
0.120
 Why?
GPI-Linked Proteins
1
2016
70
0.120
 Why?
Neoplasms, Second Primary
1
2016
115
0.120
 Why?
Adaptor Proteins, Signal Transducing
1
2018
429
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
34
0.120
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1078
0.120
 Why?
Nanoparticles
1
2021
484
0.120
 Why?
Risk Reduction Behavior
1
2016
218
0.120
 Why?
Hodgkin Disease
1
2016
139
0.120
 Why?
Phosphorylation
1
2019
1756
0.110
 Why?
Maytansine
1
2014
16
0.110
 Why?
Demography
1
2015
291
0.110
 Why?
Brain Edema
1
2014
61
0.110
 Why?
Drug Interactions
1
2015
405
0.110
 Why?
Protein Kinases
1
2015
319
0.110
 Why?
Survival Rate
2
2019
1969
0.100
 Why?
Sulfones
1
2014
110
0.100
 Why?
Randomized Controlled Trials as Topic
1
2019
1455
0.100
 Why?
Threonine
1
2013
46
0.100
 Why?
Tumor Stem Cell Assay
1
2012
34
0.100
 Why?
Glycine
1
2014
175
0.100
 Why?
Drug Evaluation, Preclinical
1
2013
182
0.100
 Why?
Time Factors
2
2020
6792
0.100
 Why?
Analgesics, Opioid
1
2021
991
0.100
 Why?
Drug Design
1
2013
166
0.100
 Why?
Methionine
1
2013
159
0.100
 Why?
Heterozygote
1
2013
292
0.100
 Why?
Disease-Free Survival
1
2014
687
0.100
 Why?
Treatment Failure
1
2013
353
0.090
 Why?
In Situ Hybridization, Fluorescence
1
2013
317
0.090
 Why?
Neovascularization, Pathologic
1
2013
301
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
326
0.090
 Why?
Cluster Analysis
1
2012
495
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
234
0.090
 Why?
Carcinoma in Situ
1
2011
49
0.090
 Why?
Computational Biology
1
2015
645
0.090
 Why?
Risk Assessment
1
2020
3429
0.090
 Why?
Cellular Senescence
1
2012
187
0.090
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
86
0.090
 Why?
Colorado
1
2020
4491
0.080
 Why?
Sequence Analysis, DNA
1
2013
811
0.080
 Why?
Mutation
2
2012
3953
0.080
 Why?
Tumor Burden
1
2010
309
0.080
 Why?
Pregnancy Trimester, Second
1
2009
80
0.080
 Why?
Keratinocytes
1
2010
248
0.080
 Why?
Mastectomy, Segmental
1
2009
93
0.080
 Why?
Pregnancy Trimester, First
1
2009
143
0.070
 Why?
Apoptosis Regulatory Proteins
1
2009
188
0.070
 Why?
Lymph Node Excision
1
2009
170
0.070
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
116
0.070
 Why?
Risk
1
2009
904
0.070
 Why?
Infusions, Intravenous
2
2019
408
0.070
 Why?
Cell Adhesion Molecules
2
2019
181
0.070
 Why?
Prognosis
2
2018
4018
0.060
 Why?
Risk Factors
1
2020
10331
0.060
 Why?
Gene Expression Profiling
1
2012
1768
0.060
 Why?
Oxazoles
1
2025
37
0.060
 Why?
Antigens, Neoplasm
2
2019
320
0.060
 Why?
Cell Cycle Proteins
2
2023
611
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
913
0.060
 Why?
Cell Cycle
2
2018
601
0.060
 Why?
Combined Modality Therapy
2
2019
1235
0.050
 Why?
Quinazolines
1
2025
249
0.050
 Why?
Follow-Up Studies
2
2025
5115
0.050
 Why?
Mesylates
1
2022
7
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
66
0.050
 Why?
Signal Transduction
2
2014
5065
0.050
 Why?
Clinical Protocols
1
2023
268
0.050
 Why?
Ligands
1
2024
664
0.050
 Why?
RNA, Small Interfering
1
2024
621
0.050
 Why?
Chimerism
1
2021
31
0.040
 Why?
Lymphocyte Subsets
1
2021
87
0.040
 Why?
Lymphoid Tissue
1
2021
75
0.040
 Why?
Liver
1
2009
1938
0.040
 Why?
Mice, SCID
1
2021
367
0.040
 Why?
SEER Program
1
2021
218
0.040
 Why?
Hormones
1
2020
142
0.040
 Why?
Mice, Inbred NOD
1
2021
601
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Tissue Distribution
1
2018
329
0.040
 Why?
Infant, Newborn
1
2009
6046
0.030
 Why?
Anemia
1
2019
170
0.030
 Why?
Pregnancy
1
2009
6731
0.030
 Why?
Cetuximab
1
2016
95
0.030
 Why?
Retreatment
1
2016
72
0.030
 Why?
Neoplasm Transplantation
1
2016
256
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
121
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
193
0.030
 Why?
Platinum
1
2016
49
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
615
0.030
 Why?
History, Ancient
1
2015
54
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
267
0.030
 Why?
Transcription Factors
1
2023
1714
0.030
 Why?
Databases, Genetic
1
2015
236
0.030
 Why?
DNA Damage
1
2017
418
0.030
 Why?
Mice, Knockout
1
2021
2999
0.030
 Why?
Biomarkers
2
2016
4158
0.030
 Why?
Quality of Life
1
2025
2868
0.030
 Why?
Opioid-Related Disorders
1
2021
504
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
251
0.020
 Why?
Drug Combinations
1
2013
344
0.020
 Why?
Phenotype
1
2021
3199
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
455
0.020
 Why?
Immunohistochemistry
1
2016
1731
0.020
 Why?
Biopsy, Needle
1
2011
189
0.020
 Why?
HT29 Cells
1
2010
40
0.020
 Why?
Enzyme Inhibitors
1
2014
838
0.020
 Why?
Transcription, Genetic
1
2017
1453
0.020
 Why?
Cohort Studies
1
2021
5718
0.020
 Why?
Proto-Oncogene Proteins
1
2014
646
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
434
0.020
 Why?
ErbB Receptors
1
2013
613
0.020
 Why?
Ki-67 Antigen
1
2010
111
0.020
 Why?
Capillary Permeability
1
2010
144
0.020
 Why?
Patient Selection
1
2013
689
0.020
 Why?
Patient Satisfaction
1
2013
650
0.020
 Why?
Positron-Emission Tomography
1
2010
295
0.020
 Why?
Membrane Proteins
1
2015
1162
0.020
 Why?
Algorithms
1
2015
1686
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3566
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2677
0.020
 Why?
Adolescent
1
2024
21463
0.010
 Why?
Brain
1
2014
2669
0.010
 Why?
Young Adult
1
2014
13126
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (287) concept(s)
_
Co-Authors Expand Description
See all (74) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)